Is ABUS or CGEM more profitable?

ABUS runs the higher net margin — ABUS at 84.23% versus CGEM at 0.00%.

How have ABUS and CGEM total returns compared?

Over the past 5 years, ABUS delivered 2.19% and CGEM delivered -7.48% annualized total return. Past performance doesn't predict future results.

Arbutus Biopharma Corp (ABUS) vs Cullinan Therapeutics, Inc. (CGEM)

A side-by-side comparison of Arbutus Biopharma Corp and Cullinan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$923M

$4.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

CGEM

Cullinan Therapeutics, Inc.

$986M

$16.04HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ABUS vs CGEM

growth of $100 · dividends reinvested · last 6y

ABUS +31.5% (+4.7%/yr)CGEM -46.4% (-9.9%/yr)ABUS compounded faster over this window

ABUS CGEM

ABUS vs CGEM: by the numbers

•CGEM is the larger company ($986M vs $923M market cap).
•ABUS is profitable (84.23% net margin) while CGEM runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	ABUS	CGEM
P/E ratio	5.98	N/A
Forward P/E	6.31	N/A
P/S ratio	5.08	N/A
P/B ratio	3.57	3.06
EV / EBITDA	6.16	N/A

Profitability

Metric	ABUS	CGEM
Gross margin	99.98%	0.00%
Operating margin	-192.08%	0.00%
Net margin	84.23%	0.00%
ROE	59.16%	-63.62%
ROIC	54.39%	-68.64%

Growth (annualized)

Metric	ABUS	CGEM
Revenue CAGR (5Y)	85.17%	N/A
Total return CAGR (5Y)	2.19%	-7.48%

Frequently asked

Is ABUS or CGEM more profitable?: ABUS runs the higher net margin — ABUS at 84.23% versus CGEM at 0.00%.
How have ABUS and CGEM total returns compared?: Over the past 5 years, ABUS delivered 2.19% and CGEM delivered -7.48% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysis Full CGEM analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio Arbutus Biopharma ROE Cullinan Therapeutics ROE Arbutus Biopharma operating margin Cullinan Therapeutics operating margin Arbutus Biopharma revenue growth Cullinan Therapeutics revenue growth Arbutus Biopharma free cash flow Cullinan Therapeutics free cash flow

Arbutus Biopharma & Cullinan Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.